3D-QSAR and docking studies on ursolic acid derivatives for anticancer activity based on bladder cell line T24 targeting NF-kB pathway inhibition

References

• Aggarwal, B. B., & Sung, B. (2011). NF-κB in cancer: A matter of life and death. Cancer Discovery, 1(6), 469–471. doi:10.1158/2159-8290.CD-11-0260
   PubMed Web of Science ®Google Scholar
• Aggarwal, B. B., Vijayalekshmi, R. V., & Sung, B. (2009). Targeting inflammatory pathways for prevention and therapy of cancer: Short-term friend, long-term foe. Clinical Cancer Research, 15(2), 425–430. doi:10.1158/1078-0432.CCR-08-0149
   PubMed Web of Science ®Google Scholar
• Ai, Y., Wang, S. T., Sun, P. H., & Song, F. J. (2011). Combined 3D-QSAR modeling and molecular docking studies on pyrrole-indolin-2-ones as Aurora A kinase inhibitors. International Journal of Molecular Sciences, 12(3), 1605–1624. doi:10.3390/ijms12031605
   PubMed Web of Science ®Google Scholar
• Alam, S., & Khan, F. (2017a). QSAR, docking, ADMET, and system pharmacology studies on tormentic acid derivatives for anticancer activity. Journal of Biomolecular Structure and Dynamics, 36(9), 2373–2390. doi:10.1080/07391102.2017.1355846
   Web of Science ®Google Scholar
• Alam, S., & Khan, F. (2017b). 3D-QSAR studies on maslinic acid analogs for anticancer activity against breast cancer cell line MCF-7. Scientific reports. 7, 6019. doi:10.1038/s41598-017-06131-0
   Google Scholar
• Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F. (2017). Bladder cancer incidence and mortality: A global overview and recent trends. European Urology, 71(1), 96–108. doi:10.1016/j.eururo.2016.06.010
   PubMed Web of Science ®Google Scholar
• Badran, B. M., Wolinsky, S. M., Burny, A., & Willard-Gallo, K. E. (2002). Identification of three NFAT binding motifs in the 5’upstream region of the human CD3-γ gene that differentially bind NFATc1, NFATc2 and NF-κB p5.
   Google Scholar
• Elidrissi, B., Ousaa, A., Aouidate, A., Zaki, H., & Ajana, M. A. (2017). 3D-QSAR studies of isatin derivatives with anti-cancer in vitro: Advanced CoMFA, CoMSIA and docking methods. Journal of Chemical Sciences, 8, 158. doi:10.4172/2150-3494.1000158
   Google Scholar
• Gadaleta, D., Mangiatordi, G. F., Catto, M., Carotti, A., & Nicolotti, O. (2016). Applicability domain for QSAR models: Where theory meets reality. International Journal of Quantitative Structure-Property Relationships (Relationships), 1(1), 45–63. doi:10.4018/IJQSPR.2016010102
   Google Scholar
• Gai, L., Cai, N., Wang, L., Xu, X., & Kong, X. (2013). Ursolic acid induces apoptosis via Akt/NF-κB signaling suppression in T24 human bladder cancer cells. Molecular Medicine Reports, 7(5), 1673–1677. doi:10.3892/mmr.2013.1364
   PubMed Web of Science ®Google Scholar
• Gilmore, T. D., & Herscovitch, M. (2006). Inhibitors of NF-κB signaling: 785 and counting. Oncogene, 25(51), 6887. doi:10.1038/sj.onc.1209982
   PubMed Web of Science ®Google Scholar
• Haskill, S., Beg, A. A., Tompkins, S. M., Morris, J. S., Yurochko, A. D., Sampson-Johannes, A. & Baldwin Jr, A. S. (1991). Characterization of an immediate-early gene induced in adherent monocytes that encodes IκB-like activity. Cell, 65, 1281–1289. doi:10.1016/0092-8674(91)90022-Q
   Google Scholar
• Hinz, M., Lemke, P., Anagnostopoulos, I., Hacker, C., Krappmann, D., Mathas, S & Scheidereit, C. (2002). Nuclear factor κB–dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. Journal of Experimental Medicine, 196, 605–617. doi:10.1084/jem.20020062
   Google Scholar
• Hua, S. X., Huang, R. Z., Ye, M. Y., Pan, Y. M., Yao, G. Y., Zhang, Y., & Wang, H. S. (2015). Design, synthesis and in vitro evaluation of novel ursolic acid derivatives as potential anticancer agents. European Journal of Medicinal Chemistry, 95, 435–452. doi:10.1016/j.ejmech.2015.03.051
   PubMed Web of Science ®Google Scholar
• Huxford, T., Huang, D.-B., Malek, S., & Ghosh, G. (1998). The crystal structure of the IκBα/NF-κB complex reveals mechanisms of NF-? B inactivation. Cell, 95(6), 759–770. doi:10.1016/S0092-8674(00)81699-2
   PubMed Web of Science ®Google Scholar
• Israël, A. (2010). The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harbor Perspectives in Biology, 2(3), a000158doi:10.1038/nri1703
   PubMed Web of Science ®Google Scholar
• Kamath, S., & Buolamwini, J. K. (2003). Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malononitrile tyrphostins as EGFR and HER-2 kinase inhibitors. Journal of Medicinal Chemistry, 46(22), 4657–4668. doi:10.1021/jm030065n
   PubMed Web of Science ®Google Scholar
• Karin, M., & Greten, F. R. (2005). NF-κB: Linking inflammation and immunity to cancer development and progression. Nature Reviews Immunology, 5(10), 749. doi:10.1038/nri1703
   PubMed Web of Science ®Google Scholar
• Khanfar, M. A., Youssef, D. T., & El Sayed, K. A. (2010). 3D-QSAR studies of latrunculin-based actin polymerization inhibitors using CoMFA and CoMSIA approaches. European Journal of Medicinal Chemistry, 45(9), 3662–3668. doi:10.1016/j.ejmech.2010.05.012
   PubMed Web of Science ®Google Scholar
• Kitamura, T., Sekimata, M., Kikuchi, S. I., & Homma, Y. (2005). Involvement of poly (ADP-ribose) polymerase 1 in ERBB2 expression in rheumatoid synovial cells. American Journal of Physiology-Cell Physiology, 289, C82–C88. doi:10.1152/ajpcell.00486.2004
   Google Scholar
• Kummar, S., & Doroshow, J. H. (2013). Molecular targets in cancer therapy. Expert Review of Anticancer Therapy, 13(3), 267–269. doi:10.1586/era.12.170
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. (2004). Lead- and drug-like compounds: The rule-of-five revolution . Drug Discovery Today Technologies, 1(4), 337–341. doi:10.1016/j.ddtec.2004
   PubMedGoogle Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(–3), 3–26. doi:10.1016/S0169-409X(00)00129-0
   Google Scholar
• Li, F., & Sethi, G. (2010). Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochimica Et Biophysica Acta (BBA)-Reviews on Cancer, 1805(2), 167–180. doi:10.1016/j.bbcan.2010.01.002
   PubMed Web of Science ®Google Scholar
• Liu, S., Misquitta, Y. R., Olland, A., Johnson, M. A., Kelleher, K. S., Kriz, R., … Mosyak, L. (2013). Crystal structure of a human IκB kinase β asymmetric dimer. Journal of Biological Chemistry, 288(31), 22758–22767. doi:10.1074/jbc.M113.482596
   PubMed Web of Science ®Google Scholar
• Li, X., Zhang, Y., Zhang, L., Xu, Y., & Xu, W. (2014). 3D QSAR and docking studies of a series of histone deacetylase inhibitors. Medicinal Chemistry Research, 23(5), 2229–2241. doi:10.1007/s00044-013-0816-9
   Web of Science ®Google Scholar
• Lombardi, L., Ciana, P., Cappellini, C., Trecca, D., Guerrini, L., Migliazza, A., & Neri, A. (1995). Structural and functional characterization of the promoter regions of the NFKB2 gene. Nucleic Acids Research, 23, 2328–2336. doi:10.1093/nar/23.12.2328
   Google Scholar
• Mak, I. W., Evaniew, N., & Ghert, M. (2014). Lost in translation: Animal models and clinical trials in cancer treatment. American Journal of Translational Research, 6, 114.
   PubMed Web of Science ®Google Scholar
• Moon, E. Y., & Park, H. (2007). B cell activating factor (BAFF) gene promoter activity depends upon co-activator. Immunobiology, 212, 637–645. doi:10.1016/j.imbio.2007.06.002
   Google Scholar
• Mukherjee, N., Houston, T. J., Cardenas, E., & Ghosh, R. (2015). To be an ally or an adversary in bladder cancer: The NF-κB story has not unfolded. Carcinogenesis, 36(3), 299–306. doi:10.1093/carcin/bgu321
   PubMed Web of Science ®Google Scholar
• Müller, C. W., Rey, F. A., Sodeoka, M., Verdine, G. L., & Harrison, S. C. (1995). Structure of the NF-κB p50 homodimer bound to DNA. Nature, 373(6512), 311. doi:10.1038/373311a0
   PubMed Web of Science ®Google Scholar
• Murumkar, P. R., Shinde, A. C., Sharma, M. K., Yamaguchi, H., Miniyar, P. B., & Yadav, M. R. (2016). Development of a credible 3D-QSAR CoMSIA model and docking studies for a series of triazoles and tetrazoles containing 11β-HSD1 inhibitors. SAR and QSAR in Environmental Research, 27(4), 265–229. doi:10.1080/1062936X.2016.1167774
   PubMed Web of Science ®Google Scholar
• Nantasenamat, C., Isarankura-Na-Ayudhya, C., & Prachayasittikul, V. (2010). Advances in computational methods to predict the biological activity of compounds. Expert Opinion on Drug Discovery, 5(7), 633–654. doi:10.1517/17460441.2010.492827
   PubMed Web of Science ®Google Scholar
• Nishi, H., Neta, G., Nishi, K. H., Akers, L. M., Rikiyama, T., Proctor, K. N. & Johnson, A. C. (2003). Analysis of the epidermal growth factor receptor promoter: the effect of nuclear factor-κB. International Journal of Molecular Medicine, 11, 49–55. doi:10.3892/ijmm.11.1.49
   Google Scholar
• Pagadala, N. S., Syed, K., & Tuszynski, J. (2017). Software for molecular docking: A review. Biophysical Reviews, 9(2), 91–102. doi:10.1007/s12551-016-0247-1
   PubMedGoogle Scholar
• Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751. doi:10.1038/nnano.2007.387
   PubMed Web of Science ®Google Scholar
• Polivka, J., Jr., & Janku, F. (2014). Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacology & Therapeutics, 142(2), 164–175. doi:10.1016/j.pharmthera.2013.12.004
   PubMed Web of Science ®Google Scholar
• Rushe, M., Silvian, L., Bixler, S., Chen, L. L., Cheung, A., Bowes, S., … Lugovskoy, A. (2008). Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site. Structure, 16(5), 798–808. doi:10.1016/j.str.2008.02.012
   PubMed Web of Science ®Google Scholar
• Shakhov, A. N., Collart, M. A., Vassalli, P., Nedospasov, S. A., & Jongeneel, C. V. (1990). Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. Journal of Experimental Medicine, 171, 35–47. doi:10.1084/jem.171.1.35
   Google Scholar
• Shen, H. M., & Tergaonkar, V. (2009). NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis, 14(4), 348–363. doi:10.1007/s10495-009-0315-0.
   PubMed Web of Science ®Google Scholar
• Shin, S. W., & Park, J. W. (2013). Ursolic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1833(3), 723–730. doi:10.1016/j.bbamcr.2012.12.005
   PubMed Web of Science ®Google Scholar
• Smith, M. F., Eidlen, D., Arend, W. P., & Gutierrez-Hartmann, A. (1994). LPS-induced expression of the human IL-1 receptor antagonist gene is controlled by multiple interacting promoter elements. The Journal of Immunology, 153, 358––3593.
   Google Scholar
• Schwenzer, R., Siemienski, K., Liptay, S., Schubert, G., Peters, N., Scheurich, P & Wajant, H. (1999). The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligad family and modulates TNF-induced activation of NF-κB and c-Jun N-terminal kinase. Journal of Biological Chemistry, 274, 19368–19374 .doi:10.1074/jbc.274.27.19368
   Google Scholar
• Shukla, A., Sharma, P., Prakash, O., Singh, M., Kalani, K., Khan, F., … Srivastava, S. K. (2014). QSAR and docking studies on capsazepine derivatives for immunomodulatory and anti-inflammatory activity. PloS One, 9(7), e100797. doi:10.1371/journal.pone.0100797
   PubMed Web of Science ®Google Scholar
• Sica, A., Tan, T. H., Rice, N., Kretzschmar, M., Ghosh, P., & Young, H. A. (1992). The c-rel protooncogene product c-Rel but not NF-kappa B binds to the intronic region of the human interferon-gamma gene at a site related to an interferon-stimulable response element. Proceedings of the National Academy of Sciences, 89, 1740–1744. doi:10.1073/pnas.89.5.1740
   Google Scholar
• Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: A Cancer Journal for Clinicians, 66(1), 7–30. doi:10.3322/caac.21332
   PubMed Web of Science ®Google Scholar
• Sultana, N. (2011). Clinically useful anticancer, antitumor, and antiwrinkle agent, ursolic acid and related derivatives as medicinally important natural product. Journal of Enzyme Inhibition and Medicinal Chemistry, 26(5), 616–642. doi:10.3109/14756366.2010.546793
   PubMed Web of Science ®Google Scholar
• Sun, S. C., Ganchi, P. A., Ballard, D. W., & Greene, W. C. (1993). NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science, 259, 1912–1915. doi:10.1126/science.8096091
   Google Scholar
• Takeshita, F., Suzuki, K., Sasaki, S., Ishii, N., Klinman, D. M., & Ishii, K. J. (2004). Transcriptional regulation of the human TLR9 gene. The Journal of Immunology, 173(4), 2552–2561. doi:org/10.4049/jimmunol.173.4.2552
   Google Scholar
• Takiar, R., Nadayil, D., & Nandakumar, A. (2010). Projections of number of cancer cases in India (2010-2020) by cancer groups. Asian Pacific Journal of Cancer Prevention: APJCP, 11(4), 1045–1049.
   PubMedGoogle Scholar
• Ten, R. M., Paya, C. V., Israel, N., Le Bail, O., Mattei, M. G., Virelizier, J. L., & Israel, A. (1992). The characterization of the promoter of the gene encoding the p50 subunit of NF-kappa B indicates that it participates in its own regulation. The EMBO Journal, 11, 195–203. doi:10.1002/j.1460-2075.1992.tb05042.x
   Google Scholar
• Thornburg, N. J., & Raab-Traub, N. (2007). Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-κB p50 homodimer/Bcl-3 complexes. Journal of Virology, 81, 12954–12961. doi:10.1128/JVI.01601-07
   Google Scholar
• Thun, M. J., DeLancey, J. O., Center, M. M., Jemal, A., & Ward, E. M. (2010). The global burden of cancer: Priorities for prevention. Carcinogenesis, 31(1), 100–110.
   PubMed Web of Science ®Google Scholar
• Tiwari, P., Mishra, B. N., & Sangwan, N. S. (2014). Phytochemical and pharmacological properties of Gymnema sylvestre: An important medicinal plant. BioMed Research International, 2014, 1. doi:10.1155/2014/830285
   Web of Science ®Google Scholar
• Tropsha, A., Gramatica, P., & Gombar, V. K. (2003). The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models. QSAR & Combinatorial Science, 22(1), 69–77. doi:10.1002/qsar.200390007
   Google Scholar
• Viatour, P., Merville, M. P., Bours, V., & Chariot, A. (2005). Phosphorylation of NF-κB and IκB proteins: Implications in cancer and inflammation. Trends in Biochemical Sciences, 30(1), 43–52. doi:10.1016/j.tibs.2004.11.009
   PubMed Web of Science ®Google Scholar
• Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998). NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 281(5383), 1680–1683. doi:10.1126/science.281.5383.1680
   PubMed Web of Science ®Google Scholar
• Wang, J., Liu, L., Qiu, H., Zhang, X., Guo, W., Chen, W., … Deng, W. (2013). Ursolic acid simultaneously targets multiple signaling pathways to suppress proliferation and induce apoptosis in colon cancer cells. PloS One, 8(5), e63872. doi:10.1371/journal.pone.0063872
   PubMed Web of Science ®Google Scholar
• Worm, M. M., Tsytsykova, A., & Geha, R. S. (1998). CD40 ligation and IL-4 use different mechanisms of transcriptional activation of the human lymphotoxin α promoter in B cells. European journal of immunology, 28, 901–906. doi:10.1002/(SICI)1521-4141(199803)28:03<901
   Google Scholar
• Wu, M. X., Ao, Z., Prasad, K., Wu, R., & Schlossman, S. F. (1998). IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival. Science, 281(5379), 998–1001. doi:10.1126/science.281.5379.998
   PubMed Web of Science ®Google Scholar
• Yin, R., Li, T., Tian, J. X., Xi, P., & Liu, R. H. (2018). Ursolic acid, a potential anticancer compound for breast cancer therapy. Critical Reviews in Food Science and Nutrition, 58(4), 568–574. doi:10.1080/10408398.2016.1203755
   PubMed Web of Science ®Google Scholar